EVIIVE is disrupting the diagnostic industry with new revolutionary technologies.
Established in 2022, our exceptional team of research specialists has dedicatedly positioned EVIIVE at the pinnacle of the BioMed Tech sector.
We are pioneering a cutting-edge platform for liquid biopsy biomarker discovery, along with assay kits tailored for individualized treatment recommendations and disease tracking. Our groundbreaking technology aims to elevate personalized diagnostic solutions.
Our commitment remains unwavering in setting the gold standard in technology, offering comprehensive insights that not only gain industry leader endorsement but also their reliance.
MEET THE TEAM
Meet our team of experts at EVIIVE, where we are dedicated to pushing the boundaries of biotechnology.
Co-Founder & CEO
Dr Kevin Yim
As a retired professional cyclist representing HK, a serial entrepreneur, and a PhD graduate in EV biology from the University of Zurich & UZH Innovation Hub, I bring experience, focus, tenacity, and hard work to EVIIVE.
Clinical & Medical Advisor
Dr Sandeep Wontakal
Physician-Scientist (MD-PhD) and Dep of Pathology lab head at Johns Hopkins University; with a passion for driving multi-disciplinary projects in pathology & molecular genetics.
OUR INNOVATIVE TECHNOLOGY
We have developed IMPASS (Immune-Pathogenesis Surveillance System), a novel and proprietary technological platform to help industry-leading companies and individuals achieve greater diagnostic and prognostic power.
IMPASS is a triple locked platform combining new revolutionary liquid biopsy analyses, advance machine learning, and novel biomarker discovery.
IMPASS has a wide range of features that were created with an aim to help personlize patient care in a quick and effective manner. In order to empower our patients to do better.
EVIIVE is continually building upon its technology, so stay in touch to learn about upgrades and other changes.
IN THE PRESS
EVIIVE secures BRIDGE-SNSF funding
Eviive is granted a generous fund to further develop extracellular vesicles as a platform to detect immune system defects and accelerate our market entry. News Link.
EVIIVE wins VENTURE KICK funding
Startups developing a low-cost breathe ventilator, 300x faster qubits, a minimally invasive diagnostic for sepsis, sustainable real estate investment, sustainable food based on fungi and fermantation each win Venture Kick funds.
EVIIVE wins MEDTECH fellowship
EVIIVE wins the UZH-BIOMEDTECH fellowship supported by the WSS foundation. And EVIIVE is offered lab space at IREM-Schlieren supported by the WYSS foundation.
New methodology changing diagnostics
Our proof of concept approach to use extracellular vesicles to detect SARS-CoV-2 infection, immune response status, and immune system effects.
Our work is proudly supported by